Table 2.
SF-36 measure | US norm | TLC (n=264) | p-value* | Effect size# | US patients only | p-value | Effect size# |
---|---|---|---|---|---|---|---|
Physical Functioning | 50 | 48.18* | 0.004 | 0.18 | 49.32 | 0.35 | 0.068 |
Role-Physical | 50 | 47.33* | <0.0001 | 0.27 (small) | 48.52* | 0.042 | 0.15 |
Bodily Pain | 50 | 49.41 | 0.35 | 0.059 | 50.19 | 0.80 | −0.019 |
General Health | 50 | 41.5* | <0.0001 | 0.85 (large) | 41.27* | <0.0001 | 0.87 (large) |
Vitality | 50 | 48.89 | 0.08 | 0.11 | 49.65 | 0.63 | 0.035 |
Social Functioning | 50 | 46.79* | <0.0001 | 0.32 (small) | 48.01* | 0.006 | 0.20 |
Role-Emotional | 50 | 46.78* | <0.0001 | 0.32 (small) | 48.15* | 0.01 | 0.18 |
Mental Health | 50 | 49.04 | 0.12 | 0.096 | 49.38 | 0.40 | 0.062 |
Physical Summary | 50 | 46.8* | <0.0001 | 0.32 (small) | 47.57* | <0.0001 | 0.24 (small) |
Mental Summary | 50 | 47.95* | 0.002 | 0.20 | 48.73 | 0.11 | 0.13 |
one sample T test shows significant difference between population and US norm (p<0.05)
effect size = difference in mean / population SD
Clinically significant effects defined as: 0.2-0.49 = ‘small’, 0.50-0.79 = ‘moderate’, >0.80 = ‘large’(8)